Protecting Our Future

ReNewVax

Welcome To Our  Investors  Page

ReNewVax Ltd (“ReNewVax”) is a next generation vaccine company, spun out of the University of Liverpool with the benefit of Innovate UK and University funding, that is developing novel vaccines that address some of the world’s most pressing bacterial infections.

Traditional vaccine development is hypothesis driven and carries high risk until clinical evidence is generated.

ReNewVax employs a rational approach to vaccine development, using analysis of clinical samples to identify protein antigens that can form the basis of an effective vaccine.

This is further derisked by including ex vivo human cell testing to confirm immunologic properties of our vaccines before testing in clinic.

The lead program in our pipeline, RVX-001, is potentially the first universal vaccine against Streptococcus pneumoniae (pneumococcus) – one of the WHO’s priority pathogens, which is a leading cause of death associated with anti-microbial resistance (AMR) globally.

Pneumococcus vaccines represent the largest vaccine market pre-pandemic, with annual sales of ca. $9.5bn.  The market is dominated by Merck and Pfizer with pneumococcal conjugate (PCV) and polysaccharide (PPSV) vaccines.

There are around 100 different serotypes (versions) of the pneumococcus and existing vaccines target ca. 20% of these.

The nature of bacteria results in a phenomenon known as serotype replacement, whereby, over time, new variants that are not susceptible to existing vaccines, become dominant in the population, replacing those serotypes that the existing vaccines have been designed to hit and reducing vaccine effectiveness.  For example, the most recent published data shows that pneumococcal disease in the EU increased by 41% over a five-year period, despite high levels of vaccination.

In addition, due to their composition, existing vaccines are complex and expensive to manufacture, resulting in high dosage costs and limiting their use globally.

RVX-001 is designed with antigens common to all pneumococcus serotypes, making it potentially the first universal pneumococcal vaccine.

Because RVX-001’s components can be produced recombinantly, the vaccine will also be cheaper to manufacture than existing vaccines.

With efficacy in animals already established and ex vivo human studies showing a strong immunogenic profile, RVX-001 is entering IND/CTA-enabling studies, with a view to going into clinical trials in early-2025.

The company is pursuing a virtual model and has established an experienced core team with a capable network of consultants and partners to support development of its programs.

In addition to RVX-001, we have 2 further pipeline programs – RVX-002 focused on Group B Streptococcus and RVX-003 focused on Group A Streptococcus.

ReNewVax is currently fundraising, looking to close a £4m funding round during 1H2023.

Pipeline 

ReNewVax is uniquely positioned to develop next-generation vaccines that will overcome the shortcomings of existing approaches. Our vaccine pipeline is aligned with the three main stages of discovery, preclinical and clinical, and is segmented into 8 key steps:

Discovery phase
Step 1 -Genomics
Step 2 – Rational Antigen discovery

Preclinical phase: Step 3 – Vaccine Candidate Validation
Step 4 – Vaccine Formulation
Step 5 – Immunogenicity and Protective Efficacy in Animal Models
Step 6 – Human PBMCs ex vivo predictive models
Step 7 – IND/CTA-enabling studies

Clinical phase
Step 8 – Phase I/II Clinical trial”

Target Selection
Lead Generation
Lead Optimization
Pre-clinical POC
IND
Phase I
Phase II
Step 6
RVX-001
S. pneumoniae (or the pneumococcus)
Into phase I in 2025
  • A unique proprietary protein-based adjuvanted formulation
  • Preclinical POC vs. Prevnar13® (PCV13 Pfizer) as well as ongoing studies with Pneumovax®23 (PPV23, Merck) and ApeXXnar ® (PCV20, Pfizer)
  • Anticipate Phase 1 top line immunogenicity, safety and tolerability results in adults by end of 2025
Target Selection
Lead Generation
Lead Optimization
Pre-clinical POC
IND
Phase I
Phase II
Step 4
RVX-002
S. agalactiae (or GBS)
Exploring mRNAseq approach POC
  • A rationally-designed vaccine formulation based on the analysis of over 15,000 publicly available genomes
  • Initiated IND-enabling activities in Q1 2021
  • Supported with grant from UKRI-GCRF and Wellcome Trust grants
Target Selection
Lead Generation
Lead Optimization
Pre-clinical POC
IND
Phase I
Phase II
Step 3
RVX-003
S. Pyogenes (or GAS)
Focus on AMR-tackling strategies
  • Lead generation completion expected in Q4 2022
  • Anticipate preclinical studies in Q1/Q2 2023

Press Releases

News

ReNewVax’s leadership team reflect on the company’s first year

Since spinning out of the University of Liverpool, ReNewVax has started to build its scientific team and progressed its vaccine programme RVX-001 towards regulatory studies that will allow clinical trials to begin. CSO Dr. Marie O’Brien and CEO Dr. Neil Murray reflect on what the company has achieved to date and what the future has in store.

|Aug 2, 2023

News

ReNewVax appears on The Northern Agenda podcast

World Immunization Week, celebrated in the last week of April, aims to highlight the collective action needed to protect people from vaccine-preventable diseases. Here, our chief scientific officer Dr Marie O’Brien discusses the importance of the event and how ReNewVax is contributing.

|May 5, 2023

News

World Immunization Week Q&A with Dr Marie O’Brien

World Immunization Week, celebrated in the last week of April, aims to highlight the collective action needed to protect people from vaccine-preventable diseases. Here, our chief scientific officer Dr Marie O’Brien discusses the importance of the event and how ReNewVax is contributing.

|Apr 28, 2023